Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam

Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans

(2015) Gary David Bowers et al.   XENOBIOTICA

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat

(2014) Eve-Irene Lepist et al.   KIDNEY INTERNATIONAL

Evaluation of the Effect of Cobicistat on theIn VitroRenal Transport and Cytotoxicity Potential of Tenofovir

(2013) Kirsten M. Stray et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

(2013) Susan L. Ford et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

(2013) W. Spreen et al.   HIV CLINICAL TRIALS

Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro

(2013) Johanna Weiss et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Long-acting injectable antiretrovirals for HIV treatment and prevention

(2013) William R. Spreen et al.   Current Opinion in HIV and AIDS

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects

(2012) Justin Koteff et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

BDDCS Applied to Over 900 Drugs

(2011) Leslie Z. Benet et al.   AAPS Journal

Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence

(2011) Andrew M. Hall et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Utilizing Drug-Drug Interaction Prediction Tools during Drug Development: Enhanced Decision Making Based on Clinical Risk

(2011) C. E. Shardlow et al.   DRUG METABOLISM AND DISPOSITION

Impact ofSLCO1B1(OATP1B1) andABCG2(BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins

(2011) Grant T. Generaux et al.   XENOBIOTICA

Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?

(2010) Hassane Izzedine et al.   AIDS

Prediction of Fluoroquinolone-Induced Elevation in Serum Creatinine Levels: A Case of Drug–Endogenous Substance Interaction Involving the Inhibition of Renal Secretion

(2010) Y Imamura et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Treatment of dyslipidemia in HIV-infected patients

(2010) Rajagopal V Sekhar et al.   EXPERT OPINION ON PHARMACOTHERAPY

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

(2010) Ivy Song et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1

(2010) P. Annaert et al.   XENOBIOTICA

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

(2009) S. Min et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction

(2009) O. A. Fahmi et al.   DRUG METABOLISM AND DISPOSITION

Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin

(2009) Anthony J Busti et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers

(2008) Jennifer J Kiser et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The Use of BDDCS in Classifying the Permeability of Marketed Drugs

(2008) Leslie Z. Benet et al.   PHARMACEUTICAL RESEARCH